RVMD
Revolution Medicines, Inc.
$186.88
-4.25 (-2.22%)
At close · Jul 10
Market Cap
$39.73B
Shares
212,596,462
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$186.88
Open$192.22
Day$184.79–192.33
52W$34.00–193.83
Avg vol 30d3.2M
Short int12.9M · 6.1% float · 3.0d
Short vol53%
Last earningsMay 6, 2026
DataFeb 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+78%
above
Price vs 50-day avg
+17%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
96%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+30%
trailing
6-month return
+52%
trailing
YTD return
+135%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $160 › 200d $105 — 50d above 200d
Institutional flow
Accumulating
36 of 518 funds reported for Jun 30 · net +335.6K sh shares · +16 new
Insider flow
Distributing
Net -$19.6M over 90 days · 100% sells
Short interest
Rising
6.06% of float · ▲ +4.9% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
518 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
−66%
Y/Y
Free cash flow
$-913.7M
Balance sheet
$383.7M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
GAAP operating expenses
· full year 2026
GAAP
Initiated
$1.7B – $1.8B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+78%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
96%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $160 › 200d $105 — 50d above 200d
Institutional flow
Accumulating
36 of 518 funds reported for Jun 30 · net +335.6K sh shares · +16 new
Insider flow
Distributing
Net -$19.6M over 90 days · 100% sells
Short interest
Rising
6.06% of float · ▲ +4.9% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
518 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $34
Now $187 · 96%
52-wk high $194
vs 200-day avg +78%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVMD
this stock
Revolution Medicines, Inc.
|
$39.73B | +134.6% | — | — | 6.1% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVMD | -1.3% | +29.6% | +51.6% | -0.2% | +134.6% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.6% | +25.5% | +42.5% | -1.3% | +123.9% |
Key facts
CIK
1628171
CUSIP
76155X100
13F (30d)
37 filings
36 filers
Visit website
Investor relations